Kamada (NASDAQ:KMDA) Shares Cross Above 50-Day Moving Average – Time to Sell?

Kamada Ltd. (NASDAQ:KMDA)’s share price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $8.31 and traded as high as $9.09. Kamada shares last traded at $8.98, with a volume of 56,942 shares changing hands.

Key Headlines Impacting Kamada

Here are the key news stories impacting Kamada this week:

• Positive Sentiment: Analyst upgrades — Sidoti raised near‑term and FY2026/FY2027 EPS forecasts, lifting expectations for profitability into 2026–27; this can support the stock over the medium term. Sidoti estimate raises
• Positive Sentiment: Dividend declared — Kamada announced a $0.25 per‑share cash dividend under a new annual dividend policy, which typically attracts income‑focused investors and reduces downside risk. Dividend press release
• Positive Sentiment: Company statement: record 2025 results — Kamada’s press release framed 2025 as record top- and bottom-line performance and said it affirms 2026 guidance, which management presents as continued double‑digit organic growth. That message can underpin investor confidence if investors focus on the company narrative. 2025 results & guidance
• Neutral Sentiment: Earnings‑call materials available — The Q4 earnings call transcript and a Yahoo/Seeking Alpha highlights piece summarize management’s strategic outlook and revenue drivers; useful for assessing whether misses were one‑offs or structural. Earnings call transcript Call highlights
• Neutral Sentiment: Short interest fell in late February — short positions declined ~17.8% (to ~136.8k shares), lowering immediate short‑squeeze risk; this is a modest technical positive/neutral factor for liquidity. (Market data)
• Negative Sentiment: Q4 miss — Reported EPS of $0.06 missed consensus ~$0.09, and reported revenue (~$44.7M) fell well short of the ~$145M analyst estimate cited in some services; that sharp revenue miss is the primary near‑term negative catalyst. Q4 miss article MarketBeat earnings summary
• Negative Sentiment: Guidance / consensus disconnect — a reported FY2026 revenue range (c.$200–205M) cited in feeds appears materially below an indicated consensus figure in the same feed, creating uncertainty and raising questions about outlook clarity; investor concern over guidance and modeling likely amplified selling. (Company guidance disclosures / market commentary)

Wall Street Analysts Forecast Growth

KMDA has been the topic of several research reports. HC Wainwright boosted their price objective on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Benchmark reiterated a “buy” rating on shares of Kamada in a report on Thursday, January 8th. Stifel Nicolaus set a $11.00 price target on Kamada in a research note on Wednesday. Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.00.

Kamada Price Performance

The business has a 50-day simple moving average of $8.38 and a two-hundred day simple moving average of $7.44. The stock has a market cap of $491.71 million, a price-to-earnings ratio of 23.75, a P/E/G ratio of 0.75 and a beta of 0.94.

Institutional Investors Weigh In On Kamada

Several hedge funds have recently added to or reduced their stakes in the business. Aristides Capital LLC increased its holdings in shares of Kamada by 4.5% in the fourth quarter. Aristides Capital LLC now owns 33,015 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 1,430 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of Kamada by 4.2% during the 3rd quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock worth $366,000 after buying an additional 2,125 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of Kamada by 1.2% during the 3rd quarter. ARK Investment Management LLC now owns 256,217 shares of the biotechnology company’s stock worth $1,779,000 after buying an additional 2,943 shares during the period. Barclays PLC grew its stake in Kamada by 417.1% in the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 3,862 shares during the last quarter. Finally, Two Sigma Investments LP grew its stake in Kamada by 4.3% in the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after buying an additional 4,504 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.